Global InformationRelatlimab information
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Lymphocyte activation gene-3 (LAG-3) |
| Clinical data | |
| Other names | BMS-986016, relatlimab-rmbw |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Antineoplastic |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
|
| DrugBank |
|
| UNII |
|
| KEGG |
|
| Chemical and physical data | |
| Formula | C6472H9922N1710O2024S38 |
| Molar mass | 145288.79 g·mol−1 |
Relatlimab is a monoclonal antibody designed for the treatment of melanoma.[3][4] It is used in combination with nivolumab to treat melanoma.[2][5]
Relatlimab is a Lymphocyte activation gene-3 (LAG-3) inhibitor.[2][5] It is under development by Bristol-Myers Squibb.[2][5] It is made using Chinese hamster ovary cells.[2]
- ^ "Notice: Multiple additions to the Prescription Drug List (PDL) [2023-12-22]". Health Canada. 22 December 2023. Retrieved 3 January 2024.
- ^ a b c d e "Opdualag- nivolumab and relatlimab-rmbw injection". DailyMed. 18 March 2022. Retrieved 22 March 2022.
- ^ Cavagnaro JA, Cosenza ME, eds. (2021). Translational Medicine: Optimizing Preclinical Safety Evaluation of Biopharmaceuticals. Boca Raton, Florida: CRC Press. ISBN 978-1-00-047185-4.
- ^ Robert C (December 2021). "LAG-3 and PD-1 blockade raises the bar for melanoma". Nature Cancer. 2 (12): 1251–3. doi:10.1038/s43018-021-00276-8. PMID 35121906. S2CID 245407697.
- ^ a b c Cite error: The named reference
Opdualag PRwas invoked but never defined (see the help page).